220 related articles for article (PubMed ID: 18039393)
21. Clinical safety of a viral vector based prostate cancer vaccine strategy.
Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
[TBL] [Abstract][Full Text] [Related]
22. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
Madan RA; Arlen PM; Gulley JL
Expert Opin Biol Ther; 2007 Apr; 7(4):543-54. PubMed ID: 17373905
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.
Morse MA; Niedzwiecki D; Marshall JL; Garrett C; Chang DZ; Aklilu M; Crocenzi TS; Cole DJ; Dessureault S; Hobeika AC; Osada T; Onaitis M; Clary BM; Hsu D; Devi GR; Bulusu A; Annechiarico RP; Chadaram V; Clay TM; Lyerly HK
Ann Surg; 2013 Dec; 258(6):879-86. PubMed ID: 23657083
[TBL] [Abstract][Full Text] [Related]
24. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
Morse MA
Curr Opin Mol Ther; 2001 Aug; 3(4):407-12. PubMed ID: 11525565
[TBL] [Abstract][Full Text] [Related]
25. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
[TBL] [Abstract][Full Text] [Related]
27. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer.
McAneny D; Ryan CA; Beazley RM; Kaufman HL
Ann Surg Oncol; 1996 Sep; 3(5):495-500. PubMed ID: 8876893
[TBL] [Abstract][Full Text] [Related]
28. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Mohebtash M; Tsang KY; Madan RA; Huen NY; Poole DJ; Jochems C; Jones J; Ferrara T; Heery CR; Arlen PM; Steinberg SM; Pazdur M; Rauckhorst M; Jones EC; Dahut WL; Schlom J; Gulley JL
Clin Cancer Res; 2011 Nov; 17(22):7164-73. PubMed ID: 22068656
[TBL] [Abstract][Full Text] [Related]
29. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Hodge JW; McLaughlin JP; Kantor JA; Schlom J
Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
[TBL] [Abstract][Full Text] [Related]
30. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.
Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Clin Cancer Res; 2004 May; 10(10):3273-81. PubMed ID: 15161680
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.
Conry RM; Khazaeli MB; Saleh MN; Allen KO; Barlow DL; Moore SE; Craig D; Arani RB; Schlom J; LoBuglio AF
Clin Cancer Res; 1999 Sep; 5(9):2330-7. PubMed ID: 10499601
[TBL] [Abstract][Full Text] [Related]
32. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules.
Kaufman HL; Kim DW; Kim-Schulze S; DeRaffele G; Jagoda MC; Broucek JR; Zloza A
Hum Gene Ther; 2014 May; 25(5):452-60. PubMed ID: 24484178
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
[TBL] [Abstract][Full Text] [Related]
34. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer.
Hallermalm K; Johansson S; Bråve A; Ek M; Engström G; Boberg A; Gudmundsdotter L; Blomberg P; Mellstedt H; Stout R; Liu MA; Wahren B
Scand J Immunol; 2007 Jul; 66(1):43-51. PubMed ID: 17587345
[TBL] [Abstract][Full Text] [Related]
36. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.
Kaufman HL; Cohen S; Cheung K; DeRaffele G; Mitcham J; Moroziewicz D; Schlom J; Hesdorffer C
Hum Gene Ther; 2006 Feb; 17(2):239-44. PubMed ID: 16454657
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Gulley JL; Heery CR; Madan RA; Walter BA; Merino MJ; Dahut WL; Tsang KY; Schlom J; Pinto PA
Cancer Immunol Immunother; 2013 Sep; 62(9):1521-31. PubMed ID: 23836412
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
[TBL] [Abstract][Full Text] [Related]
39. Carcinoembryonic antigen-based vaccines.
Marshall J
Semin Oncol; 2003 Jun; 30(3 Suppl 8):30-6. PubMed ID: 12881810
[TBL] [Abstract][Full Text] [Related]
40. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
